BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor conferences in November.
Details are as follows:
Stifel Healthcare Conference, November 14-15, 2023
One-on-One Investor Meetings November 14, 2023
Presentation: November 14, 2023 at 1:50pm EST
Jefferies London Healthcare Conference, November 14-16, 2023
One-on-One Investor Meetings November 15-16, 2023
Piper Sandler 35th Annual Healthcare Conference, November 28-30, 2023
One-on-One Investor Meetings November 29, 2023
Presentation: November 29, 2023 at 11:00am EST
The presentation webcasts will be available on the Company's Events & Presentations page on their website at www.ikenaoncology.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.
About Ikena Oncology
Ikena Oncology® is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a TEAD1 selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's additional research spans other targets in the Hippo pathway as well as the RAS signaling pathway, including developing IK-595, a novel MEK-RAF inhibitor. ...